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Abstract Hydroelectrolytic disorders are one of the most
common metabolic complications in cancer patients.
Although often metabolic alterations affecting various ions
are part of the manifestations of the oncological disease,
even in the form of paraneoplastic syndrome, we must not
forget that very often, these disorders could be caused by
various drugs, including some of the antineoplastic agents
most frequently used, such as platin derivatives or some
biologics. These guidelines review major management of
diagnosis, evaluation and treatment of the most common
alterations of sodium, calcium, magnesium and potassium
in cancer patients. Aside from life-sustaining treatments,
we have reviewed the role of specific drug treatments
aimed at correcting some of these disorders, such as
intravenous bisphosphonates for hypercalcemia or V2
receptor antagonists in the management of syndrome
of inappropriate antidiuretic hormone secretion-related
hyponatremia.
Keywords Hydroelectrolytic disorders  Hyponatremia 
SIADH  Hypercalcemia
Introduction
Hydroelectrolytic disorders are one of the most common
metabolic complications in cancer patients. Although often
metabolic alterations affecting various ions are part of the
manifestations of the oncological disease, even in the form
of paraneoplastic syndrome, we must not forget that very
often, these disorders could be caused by various drugs,
including some of the antineoplastic agents most frequently
used, such as platin derivatives or some biologics. The
frequently nonspecific clinical manifestations require
careful diagnosis and evaluation. With regard to treatment,
apart from support measures used to correct hydroelectro-
lytic alterations, it is now of special interest the appearance
of drugs that can specifically correct such alterations
including bisphosphonates, more powerful in the case of
hypercalcemia, and more recently V2 receptor antagonists
to correct syndrome of inappropriate antidiuretic hormone
secretion (SIADH) hyponatremia. Below is a brief review
of the main alterations of sodium, calcium, magnesium and
potassium in cancer patients, with recommendations for
each one based on the grade of evidence.
Hyponatremia
Definition
Hyponatremia is defined as a serum sodium concentration
below 135 mmol/l (mM). From a biochemical point of
view, recent consensus considers hyponatremia as ‘‘mild’’
if values are between 130 and 135 mmol/l; ‘‘moderate’’
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between 120 and 129 mmol/l and ‘‘severe’’ if below
120 mmol/l. As for the symptoms of hyponatremia, the
condition could be classified as mild, moderate or severe
according to their intensity [1]. Regarding the time for
disease development, hyponatremia is considered ‘‘acute’’
if developed in less than 48 h or ‘‘chronic’’ if developed
over a longer time (evidence level IV, recommendation
grade D).
Etiology and pathophysiology
The primary pathophysiological mechanism of hyponatre-
mia is a fluid balance disorder with a relative excess of
body water compared to the total sodium content. Nor-
mally, it is caused by a vasopressin dysfunction—antidi-
uretic hormone or ADH—the activity of which is required
for developing hyponatremia. There are three types of
hyponatremia according to serum osmolarity: iso-osmolar
hyponatremia, hyperosmolar isonatremia and hypotonic or
hypo-osmolar hyponatremia. Hypotonic hyponatremia is
most frequently encountered in clinical practice, especially
in cancer patients. The most frequent cause of hypotonic
hyponatremia in oncological patients is a SIADH, a para-
neoplastic syndrome that can occur in many tumor types,
mainly in lung cancer cases. There is a consensus on
pathophysiological differentiation of hyponatremia, first of
all based on serum osmolarity, prior to preparing a treat-
ment plan, which is why initial diagnosis should start with
the correct characterization of hyponatremia (evidence
level IV, recommendation grade D).
SIADH definition
The definition of SIADH should meet the following crite-
ria: (a) hypotonic hyponatremia with clinical euvolemia;
clinical criteria for euvolemia are the absence of signs of
hypovolemia (normal eye pressure values, normal venous
pressure, no orthostatism) and no signs of hypervolemia
either (ascites, edemas); (b) no diuretic intake; (c) no
hypothyroidism, no adrenal insufficiency (hypocortisolism)
or renal failure; (d) absence of physiological stimuli for
ADH secretion (recent surgery, severe pain, ADH secretion
stimulating drugs, etc.); (e) consistent biochemical data:
serum Na \135 mmol/l; plasma osmolarity \275 mOsm/
kg; urine osmolarity [100 mOsm/kg; urinary Na [40 m-
mol/l (in the presence of dietary sodium). Various expert
committees have prepared consensus documents estab-
lishing that the diagnosis of SIADH in cancer patients
should include each and every one of the above-mentioned
items [1–5]. In the case of a clinical suspicion of SIADH,
ion concentration and osmolarity should be determined in
plasma and urine (evidence level IV, recommendation
grade D).
Therapeutic management of SIADH in oncological patients
Acute and/or severe hyponatremia Acute and/or severe
hyponatremia is hyponatremia with mild/severe symptoms
and/or hyponatremia \48 h. (SNa \120 mmol/l).
Our therapeutic choice should be based on the clinical
condition, independently of the time to develop hypona-
tremia (acute/chronic) or of the severity confirmed by
laboratory tests (mild/moderate/severe), although usually
there is a correlation.
In the case of clinically severe hyponatremia or if SNa is
below 120 mmol/l, it is recommended to initiate treatment
at the hospital with an IV of 3 % normal saline hypertonic
solution (SHS).There are no randomized or control trials
confirming the efficacy of this method, but at least five
series of cases and expert recommendations consider this
choice as a first-line treatment under these circumstances
[1–5]. It is recommended not to exceed sodium correction
levels during the whole treatment duration, especially with
hypertonic saline solution (HSS): the maximum plasma
sodium augmentation level indicated is 10 mmol/l in 24 h
and 18 mmol/l in 48 h (evidence level IV, recommendation
grade D) [1–6].
During corrective treatment with HSS, the use of any
other hyponatremia-specific treatment should be avoided,
with the exception of furosemide which will be used in
case of overload and heart failure (Evidence level IV,
Recommendation Grade D).
Mild/moderate hyponatremia Mild/moderate hyponatre-
mia includes mild/moderate symptoms and/or hyponatre-
mia [48 h (SNa [120 mmol/l).
The treatment goal is to normalize sodium values and
improve symptoms in a situation that is not life threatening.
Several treatment options are considered and, in any case,
the recommended correction levels should always be taken
into account.
Water restriction (WR) consists of the administration of
a maximum amount of fluids of 800 ml/day. It is recom-
mended by expert consensus [2] as an initial measure, even
though there are no confirming studies (evidence level IV,
recommendation grade D). Nevertheless, this is not
incompatible with certain cancer treatments of tumors
causing SIADH that require proper hydration. This is why
there are expert groups that do not recommend the use of
WR in SIADH secondary to chemosensitive neoplasias
receiving specific treatments (evidence level IV, recom-
mendation grade D).
Selective vasopressin V2 receptor antagonists, in partic-
ular tolvaptan, are recommended in patients who are not
candidates for WR and whose clinical situation might last for
a few days, more specifically cancer-associated chronic
SIADH cases. This approval stems from the publication of
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results from two randomized placebo control clinical trials,
in which its efficacy was demonstrated in the case of hypo-
natremia (SALT 1 and 2 studies). In subsequent analyses, the
efficacy was confirmed in the case of patients with hypo-
natremia secondary to SIADH [6, 7]. There are two sys-
tematic reviews of studies that compare V2 antagonists with
placebo (a total of 15 studies were included in both reviews,
out of which only the SALT study was a control one) and five
comparative studies published later, demonstrating a glob-
ally positive effect in favor of the V2 antagonist regarding
the elevation of serum sodium levels with no impact on
survival and with not a single case of osmotic pontine
demyelination. The reviews outline the heterogeneity of the
studies as well as possible population and treatment biases
(evidence level 1b, recommendation grade B).
The use of other pharmaceutical drugs recommended for
the treatment of hyponatremia is more controversial in
the SIADH scenario: there are no meta-analyses or sys-
tematic reviews to assess the efficacy of lithium salts, urea,
demeclocycline or loop diuretics. Their possible recom-
mendation by consensus guidelines is based exclusively on
acase series published [2] (evidence level IV, recommen-
dation grade D).
Recently, Spanish oncologists have published an algo-
rithm for the treatment of hyponatremia, specifically
designed for cancer patients. See Fig. 1a,b.
Calcium disorders
Hypercalcemia
Hypercalcemia is a common disorder in patients with
cancer, occurring in approximately 20–30 % of cases,
especially in the inpatient setting. The most common
cancers associated with hypercalcemia are breast and lung
cancer and multiple myeloma. Patients with hypercalcemia
of malignancy have a poor prognosis.
Fig. 1 Treatment algorithm for hyponatremia in cancer patients. Taken from 1.
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Etiology, pathophysiology and clinical manifestations
Hypercalcemia can occur by three mechanisms: osteolytic
metastases with local release of cytokines (including
osteoclast activating factors); tumor secretion of parathy-
roid hormone-related protein (PTHrP) and tumor produc-
tion of 1,25-dihydroxyvitamin D (calcitriol) [8]. Calcium
in serum is bound to proteins. As a result, total serum
calcium concentrations in patients with changes in serum
albumin levels may not accurately reflect the physiological
calcium concentration. The normal values are between 8.5
and 10.5 mg/dl (2.2–2.6 mmol/l).
Hypercalcemia may be associated with a broad spectrum
of clinical manifestations, from few or no symptoms in
patients with mild chronic hypercalcemia to severe disor-
ders and coma. The degree of hypercalcemia, along with
the rate of rise of serum calcium concentration, often
determines symptoms and the urgency of therapy [9].
Treatment
The main initial measures to treat hypercalcemia include
saline hydration and administration of calcitonin and a
bisphosphonate. Sometimes, the use of glucocorticoids
could be useful [10].
Patients with asymptomatic hypercalcemia (cal-
cium\12 mg/dl) do not require immediate treatment. Patients
may be advised about factors that can aggravate hypercalcemia
(level of evidence IV, grade of recommendation D).
Asymptomatic or mildly symptomatic patients with calcium
levels between 12 and 14 mg/dl require saline hydration, at an
initial rate of 200 ml/h with urine control and prednisone can
be added at a dose of 40 mg/day. Sometimes, loop diuretics
may be used when patients have edema. Bisphosphonates are
considered only if patients have bone metastases [11] (level of
evidence IV. grade of recommendation D).
Patients with symptomatic hypercalcemia and/or calcium
level greater than 14 mg/dl require more aggressive therapy.
Volume expansion with isotonic saline to maintain urine output
at 100 ml/h and 4 mg of zoledronic acid over 15 min is the
most effective treatment [12]. (level of evidence IV, grade of
recommendation D). Loop diuretics are recommended only if
there is renal failure or heart failure. Calcitonin (4 UI/kg) could
be useful if there is no change in calcium levels after the first
24–48 h. Dialysis is reserved for severe hypercalcemia with
calcium levels greater than 18 mg/dl.
Hypocalcemia
Etiology and clinical manifestations
Although there are multiple etiologies of hypocalcemia in
oncological patients, one of the most frequent situations is
hypocalcemia secondary to hypomagnesemia produced by
the administration of treatments such as cisplatin or ce-
tuximab. Clinical manifestations depend on the degree of
hypocalcemia and the speed with which it is established.
Chronic hypocalcemia is usually asymptomatic until a
trigger occurs. Irritability, memory disorders, neurosis,
psychosis, abnormal electrocardiogram (ECG) and tetany
can be the most common signs and symptoms of hypo-
calcemia [13].
Treatment
Treatment must aim at correcting serum calcium and
relieve patient symptoms. For mild symptomatic hypocal-
cemia, increasing oral calcium intake (250–500 mg/6 h) is
recommended. For moderate and severe symptomatic
hypocalcemia, the most recommended measures in an
emergency are administration of 1–2 g of calcium gluco-
nate 10 % over 10–20 min and then maintenance with
1 mg/kg/h. Concurrent hypomagnesemia must be treated at
the same time.
Magnesium disorders
Magnesium (Mg) is the fourth most abundant cation in the
human body and the second one after potassium in the intra-
cellular compartment [14]. It is essential for many enzymatic
and metabolic processes. Mg concentration in plasma is in a
narrow range between 1.7 and 2 mg/dl (0.7–1.4 mmol/l or
1.5–1.9 mEq/l) and homeostasis depends on the balance
between intestinal absorption and renal excretion.
Hypomagnesemia
Definition
Hypomagnesemia is defined as Mg plasma concentration
below 1.7 mg/dl (\0.75 mmol/l or \1.5 mEq/l). Mild–
moderate hypomagnesemia values range between 1.6 and
1 mg/dl and severe below 1 mg/dl.
Etiology and pathophysiology
Mg deficiency can be caused by three pathophysiological
mechanisms [15]: decreased intake (dietary factor);
diminished absorption due to resection of small intestine,
cholestasis, pancreatic failure, diarrhea, stoma, fistula and
others; and increased excretion such as in the case of
alcoholism, diabetes mellitus, interstitial nephritis, polyuric
phase of acute tubular necrosis, hyperthyroidism and
hyperparathyroidism. This mechanism also occurs when
nephrotoxic drugs are used such as aminoglycoside
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antibiotics, amphotericin, cyclosporine, loop diuretics and
in cancer patients treated with some antitumor drugs, in
particular cisplatin (CDDP) and anti-EGFR monoclonal
antibodies (mAb).
Hypomagnesemia due to CDDP is related to the
cumulative dose [16] and it is considered that the drug
interferes with renal absorption of Mg through a lesion of
the distal convoluted tubule (DCT), although some studies
suggest that hypomagnesemia associated to CDDP could
be the result of the gastrointestinal loss of Mg and not a
renal loss [17].
Hypomagnesemia is also an adverse effect of cancer
treatment with biologics, in particular anti-EGFR mAb
(cetuximab and panitumumab). The risk of hypomagnese-
mia is related to the length of treatment and in general is
reversible [18]. A meta-analysis estimates that the world
incidence is 17 % [19].
Clinical manifestations
Most patients with hypomagnesemia have no symptoms, as
they usually do not appear until the Mg plasma concen-
tration drops below 1.2 mg/dl; furthermore, hypomagne-
semia is accompanied by other electrolyte disorders, such
as hypopotassemia and hypocalcemia, which makes it
difficult to distinguish clinical manifestations due only to
Mg deficit. The most frequent symptoms of hypomagne-
semia are above all, cardiovascular (nonspecific ECG
alterations such as QT interval prolongation, T-wave and
U-wave changes among others), and neuromuscular
(paresis, tremor, paresthesia, tetany, spasms, nystagmus or
convulsions) [20].
Treatment
It is not possible to provide recommendations based on
tests for administration and dosing of Mg during or after
treatment with CDDP or anti-EGFR mAb, but all authors
reviewed agree that hypomagnesemia must be corrected
(level of evidence IV, grade of recommendation D).
Some authors consider it is appropriate to prophylac-
tically administer Mg routinely from the start of treat-
ment with CDDP during the pre- or post-hydration phase
[21]. For replacement, if the patient is asymptomatic or
hypomagnesemia is not very severe (Mg [1 mg/dl), the
oral route is the first choice, preferably with preparations
such as magnesium chloride, magnesium lactate or
magnesium oxide. In symptomatic cases or when the Mg
concentration is \1 mg/dl, the intravenous route is ade-
quate and the preparation of choice is magnesium sul-
fate. (level of evidence IV, Grade of recommendation
D). (Table 1).
Mg plasma levels should be monitored; an overdose
could cause oliguria, diminished level of consciousness and
areflexia. Concomitant hypocalcemia and hypopotassemia
should also be corrected. Patients with renal failure should
receive 50 % of the usual Mg dose if serum creatinine is
higher than 2.
Table 1 Empirical recommendations for Mg replacement according to serum levels
1. Correction of Mg deficit:
1a. Severe HypoMg (\1 mEq/l) with life-threatening symptoms:
Administer 16 mEq IV for 1 min of magnesium sulfate.
Then, 4 ml of magnesium sulfate 500 mg (4 mEq/ml) in 250 ml of 0.9 % saline solution or 5 % dextrose
Continue with IV dose as per regime as described in the next section.
1b. Severe HypoMg \1 mEq/l with no life-threatening symptoms:
First day: 1 mEq/kg and then 0.5 mEq/kg/day for 2–5 days until correction.
Administer magnesium sulfate 500 mg (4 mEq/ml) in 250 ml of 0.9 % saline solution or 5 % dextrose at administration intervals of 1.5 h
and speed B1.2 mEq/min. Increase infusion time to 4 h if undesirable effects appear such as hypotension.
1c. Hypomagnesemia [1 mEq/l and \1.5 mEq/l without symptoms:
Start with oral route; diarrhea is a limiting adverse effect, but infrequent at a dose of \80 mEq/24 h and also reduced if dose is increased
gradually and if Mg is administered after meals. No oral form is indicated for replacement of Mg and it is usually used as antacids or
laxatives.
Magnesium oxide tablets: start with 400 mg twice a day with meals and increase dose every week by 400 mg/day. Maximum dose:
400 mg/4 times a day (80 mEq/24 h); there is also oral magnesium chloride and magnesium lactate. If using magnesium oxide oral
suspension: 5 ml/4 times a day with meals (56 mEq/24 h).
Consider 6–12 months of treatment to replace Mg deficit.
2. Maintenance for oral correction.
Used to prevent recurrence of deficit. Oral Mg is prescribed in doses of approximately 48 mEq/24 h, divided into various intakes with meals.
Adapted from Crosby et al. [16].
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Hypermagnesemia [22, 23]
Hypermagnesemia is any increase in the value of plasma
Mg above 2 mg/dl. It is rare in clinical practice, even in
patients with renal failure. It is considered mild if between
2.3 and 3.6 mg/dl, moderate between 3.6 and 4.8 mg/dl,
serious between 4.8 and 7.2 mg/dl, severe between 7.2 and
12 mg/dl and very severe above 12 mg/dl.
The main causes are chronic renal failure and some
cases of acute renal failure, Mg overdose (intoxication),
adrenal insufficiency, and hypercatabolic states and tumor
lysis syndrome (TLS).
Clinical manifestations
It is usually asymptomatic until serum Mg exceeds 4 mg/
dl. Between 5 and 8 mg/dl, it may cause nausea and
vomiting, skin rash, bradycardia and hypotension. If more
severe, it can lead to the elimination of osteotendinous
reflexes and somnolence. Above 15 mg/dl, it causes
respiratory depression and muscular paralysis, and over
20 mg/dl can cause cardiac arrest with asystolia.
Treatment
If asymptomatic, the recommendation is to suspend the
administration of Mg. If intense and symptomatic, dialysis
is indicated and cardiorespiratory support may be neces-
sary. If the clinical situation is severe, treatment may be
initiated with IV calcium gluconate as Mg antagonist




Potassium imbalances are potentially life –threatening;
therefore, values found outside of the normal range will
typically require immediate therapeutic action and a com-
prehensive search for an underlying cause. More clinical
conditions are associated with aberrant potassium metabo-
lism, and patients with cancer are at particular risk for both
those found in the general population as well as those that are
tumor or treatment related. Because of the multiple factors
involved, the following guideline encompasses our general
practices for potassium homeostasis. Its evidence comes
from documents or opinions of committees of experts and/or
clinical experiences of authorities of prestige; so all the
recommendations about potassium disorders have level of
evidence IV and grade of recommendation D.
Potassium is the most abundant intracellular cation in the
body, with approximately 98 % of the body’s potassium
found intracellularly and only 2 % present extracellularly. In
Fig. 1, the regulators of potassium distribution between
intracellular and extracellular compartment appears. Potas-
sium plays an important role in many biochemical processes,
and in the excitatory properties of the membranes of muscle
and nerve cells. Normal serum potassium levels are between
3.6 and 5.0 mmol/L. The kidney is the major route of
potassium excretion, accounting for 90 % of potassium loss
daily. The remaining 10 % is excreted through the gastro-
intestinal tract. The kidney is, therefore, responsible of the
long-term potassium homoeostasis, as well as maintenance
of serum potassium concentration [24–26].
Workup of potassium imbalances
It is necessary to evaluate the adequacy of the renal
response to potassium; it is therefore important that urinary
potassium to serum potassium ratio be corrected for urinary
concentration. This ratio is referred to as transtubular
potassium gradient or TTKG. TTGK [5 in hyperkalemia
and \1 in hypokalemia. The cutoff values of [5 or \1 are
indicative of non-renal cause for K? disturbances. This
formula can canot be used if urine is more diluted than the
serum or contains very little sodium. The next step is to






Hyperkalemia is defined as serum potassium greater than
5.0 mmol/l. The possible causes of hyperkalemia are shown
in Fig. 1. Hyperkalemia is often asymptomatic and is dis-
covered on routine laboratory test. Patients with severe
hyperkalemia (K ? [6.5 mmol/L) may present with gen-
eralized weakness, paralysis and cardiac arrhythmia. Gen-
erally, the severity of clinical presentation correlates with
the severity of hyperkalemia and is reflected in ECG
changes. The ECG changes related with the K? serum level
are: Mild and moderate (6, 5 mEq/l K ?) cause peaking of
the T-wave; severe (C7 mEq/lK ?) is related with pro-
longation of PR and QRS interval, loss of P-wave and
marked widening of QRS; and extreme (C8 mEq/l K ?)
can show sine wave and ventricular fibrillation.
Management of hyperkalemia (Fig. 2)
In the presence of ECG changes, hyperkalemia should be
considered an emergency and treatment should begin
immediately with calcium gluconate infusion. This should
be followed by use of insulin and glucose to help shift
1056 Clin Transl Oncol (2014) 16:1051–1059
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potassium into the cell. The next step is removal of
potassium from the body. Table 2 summarizes emergency
treatment of severe hyperkalemia.
When hyperkalemia is due to tubular defect in
K? secretion in association with renal failure, we must
consider [27]: hydration and volume expansion to increase
urine flow rate and sodium delivery to exchange site; use of
loop diuretics to increase sodium delivery and stimulate
potassium excretion; restriction of dietary potassium intake
to nearly 60 mmol/day and use of oral mineralocorticoids
such as fludrocortisone in supraphysiological doses.
In cancer patients, it is important to recognize factitious
or pseudohyperkalemia as a consequence of marked leuc-
ocytosis or thrombocytosis associated with some malig-
nancies or secondary to therapy. Pseudohyperkalemia can
be diagnosed when the serum potassium exceeds that
obtained from plasma by more than 0.4 mmol/L. It is typ-
ically seen when there is marked leucocytosis (C100 9
109 L-1) or thrombocytosis (C1.000 9 109 L-1). It has
been reported in acute and chronic leukemias and myelo-
proliferative disorders (polycythemia vera, myelofibrosis)
[28, 29].
Table 2 Treatment of hyperkalemia
Mechanism of action Therapy Dose and administration Onset/duration
I. Membrane stabilization
(cardiac injury)
Calcium: calcium gluconate 10 % 10 ml iv in 2–5 min 5–10 min/
30–60 min
II. Shift of potassium
intracellularly
Insulin ? glucose 10U regular insulin iv ? 50 g of glucose (500 ml 10 %
or 50 ml 50 % (Glucosmon) iv
15–30 min/6–8 h
b2-adrenergic agonist: salbutamol 0.5 mg 100 ml glucose 5 % in 15 min iv 10–20 mg
(2–4 ml) nebulized in 10 min
5–8 min/2–3 h
Sodium bicarbonate (especially in
acidemia)
Bicarbonate 1/6 M, 250–500 ml or 50 ml 1 M iv 30–60 min/6–8 h
II. Removal of potassium Chelating agents: sodium or
calcium polystyrene sulfone
Oral:15–50 g/4–6 h (3–6 spoons with water) 1 h/4–6 h
Enema: 30–100 g/4–6 h (dissolved in 250 ml) 1 h/12 h
Loop diuretic: furosemide,
torasemide
40–200 mg iv 10–100 mg iv with control of renal
function
30 min/8 h
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Fig. 2 Clinical approach to potassium imbalances (adapted from Bear and Neil [29])
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Tumor lysis syndrome (TLS)
TLS is the clinical and laboratory sequelae that result from
the rapid release of intracellular contents of dying cancer
cells. It is characterized by the release of potassium,
phosphorous and nucleic acids from cancer cells into the
blood stream, with the potential to cause hyperkalemia;
hyperphosphatemia and secondary hypocalcemia; hyper-
uricemia; and, should usual homeostatic mechanisms fail,
death. TLS most commonly follows treatment of hemato-
logic malignancies, such as acute lymphocytic or lym-
phoblastic leukemia, acute myeloid leukemia and Burkitt
lymphoma, but also occurs after treatment of other bulky or
rapidly growing tumors, particularly if the patient is highly
sensitive to the effects of cytotoxic chemotherapy.
The Cairo–Bishop criteria define this syndrome in the
laboratory (uric acid C8 mg/dl, potassium C6 mEq/dl,
phosphorous C4, 6 mg/dl and calcium B7 mg/dl) and
clinically (acute kidney insufficiency, cardiac arrhythmia,
seizure, tetany or other symptomatic hypocalcemia).
Patients must meet more than two of four laboratory cri-
teria in the same 24-h period within 3 days before to 7 days
after chemotherapy initiation. A [25 % increase from
‘‘baseline’’ laboratory values is also acceptable. In the TLS
the rapid liberation of potassium into the extracellular fluid
will lead to severe hyperkalemia if it exceeds the normal
homeostatic uptake of potassium into the liver and muscle
cells [29] The therapy should be directed at increasing the
clearance of toxic intracellular contents. Prophylactic
therapy depends on the risk for TLS given specific patient
and disease characteristics. All patients at risk should
receive judicious volume repletion and allopurinol before
initiation of chemotherapy, with frequent laboratory
assessment after the start of chemotherapy.
Hypokalemia
Hypokalemia (serum potassium level 3.5 mmol/l or lower)
is perhaps the commonest electrolyte abnormality con-
fronted by the clinician and also in cancer patients
decreased intake, increased translocation into the cells, or,
most often, increased losses in the urine, gastrointestinal
tract or sweat can lead to a reduction in the serum potassium
concentration (Fig. 1). Similar to hyperkalemia, hypokale-
mia is often asymptomatic, especially in patients with mild
hypokalemia (serum potassium 3.0–3.5 mmol/l). Patients
with severe hypokalemia (serum potassium of less than
2.5 mmol/l) usually present with generalized weakness and
severe hypokalemia can precipitate rhabdomyolysis that
manifests as muscle tenderness and swelling. Cardiac
arrhythmias are common in hypokalemia. In moderate to
severe hypokalemia, changes in ECG are minimal and often
limited to the presence of a U-wave [30, 31].
Management of hypokalemia (Fig. 2)
The treatment has two objectives: replacement of potas-
sium and potassium loss correction. The treatment depends
on the severity of hypokalemia [31]. In mild hypokalemia
(K? 3–3.5 mmol/l), deficiencies can be corrected by foods
rich in the element or by supplemental oral potassium. A
dosage of 40–100 mmol/d is sufficient for its treatment.
For moderate hypokalemia (2–3 mmol/l), oral potassium
replacement such as potassium chloride, potassium phos-
phate or potassium bicarbonate is recommended. In cases
of severe hypokalemia (K? \2.5 mmol/l), potassium is
given intravenously, but the rate of potassium administra-
tion should not exceed 20 Eq/h (100–150 mEq/day). The
concentration of potassium in serum should not exceed
30 mEq per each 500 cc of serum. 20 mmol/day of
potassium in oral form per day is generally sufficient to
maintain serum potassium concentration within the normal
range in patients with increased loss (diuretic treatment)
[31].
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